In a stage III trial of dabrafenib-trametinib versus monotherapy with dabrafenib in mutated BRAF V600E/K melanoma, dual therapy was shown to have improved progression-free survival of 9.3 versus 8.8 months, response rate of 67% versus 51%, and overall survival at 6 months of 93% versus 85% when compared to dabrafenib monotherapy (19). The gene discussed is BRAF; the disease is melanoma.